Kingstone Capital Partners Texas LLC Makes New Investment in Danaher Corporation $DHR

Key Points

• Kingstone Capital Partners Texas LLC purchased 467,707 shares of Danaher Corporation, valued at approximately $92.39 million, representing about 0.07% of the company's total shares.
• Danaher reported earnings per share (EPS) of $1.80, surpassing analyst expectations, with a quarterly revenue of $5.94 billion, reflecting a 3.4% increase year-over-year.
• The company will pay a quarterly dividend of $0.32 per share on October 31st, with an annualized dividend yield of 0.7%.

Kingstone Capital Partners Texas LLC bought a new stake in shares of Danaher Corporation (NYSE:DHR - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 467,707 shares of the conglomerate's stock, valued at approximately $92,391,000. Kingstone Capital Partners Texas LLC owned approximately 0.07% of Danaher at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the stock. Hills Bank & Trust Co lifted its holdings in Danaher by 0.3% in the 1st quarter. Hills Bank & Trust Co now owns 18,015 shares of the conglomerate's stock worth $3,693,000 after purchasing an additional 53 shares during the last quarter. Sageworth Trust Co raised its holdings in Danaher by 2.3% in the 1st quarter. Sageworth Trust Co now owns 2,404 shares of the conglomerate's stock worth $493,000 after acquiring an additional 54 shares during the period. 1834 Investment Advisors Co. raised its holdings in Danaher by 3.3% in the 1st quarter. 1834 Investment Advisors Co. now owns 1,666 shares of the conglomerate's stock worth $342,000 after acquiring an additional 54 shares during the period. Bruce G. Allen Investments LLC grew its position in shares of Danaher by 13.1% in the second quarter. Bruce G. Allen Investments LLC now owns 467 shares of the conglomerate's stock valued at $92,000 after purchasing an additional 54 shares during the last quarter. Finally, Rakuten Securities Inc. grew its position in shares of Danaher by 33.3% in the first quarter. Rakuten Securities Inc. now owns 224 shares of the conglomerate's stock valued at $46,000 after purchasing an additional 56 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

DHR has been the topic of a number of research analyst reports. Scotiabank raised Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 target price on the stock in a report on Friday, July 11th. Wall Street Zen upgraded shares of Danaher from a "hold" rating to a "buy" rating in a research note on Friday, June 27th. Wells Fargo & Company lowered their price objective on shares of Danaher from $210.00 to $205.00 and set an "equal weight" rating on the stock in a research note on Wednesday, July 23rd. UBS Group decreased their price target on shares of Danaher from $240.00 to $225.00 and set a "buy" rating on the stock in a research report on Wednesday, July 23rd. Finally, Guggenheim restated a "buy" rating and issued a $250.00 price target on shares of Danaher in a research report on Wednesday, July 23rd. Seventeen equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $245.91.

Insider Activity at Danaher

In other news, Director Teri List sold 2,778 shares of the business's stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total value of $586,324.68. Following the sale, the director owned 20,751 shares in the company, valued at approximately $4,379,706.06. The trade was a 11.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 11.10% of the company's stock.

Danaher Price Performance

Shares of Danaher stock traded down $2.99 during trading on Monday, hitting $190.30. 1,686,417 shares of the company's stock traded hands, compared to its average volume of 4,136,527. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.22. The firm's fifty day moving average price is $200.17 and its 200 day moving average price is $198.18. Danaher Corporation has a twelve month low of $171.00 and a twelve month high of $279.90. The company has a market cap of $136.26 billion, a PE ratio of 40.49, a PEG ratio of 2.70 and a beta of 0.75.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, beating analysts' consensus estimates of $1.64 by $0.16. The company had revenue of $5.94 billion for the quarter, compared to the consensus estimate of $5.83 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The company's quarterly revenue was up 3.4% on a year-over-year basis. During the same period in the previous year, the business earned $1.72 earnings per share. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Analysts forecast that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be paid a $0.32 dividend. This represents a $1.28 annualized dividend and a dividend yield of 0.7%. The ex-dividend date is Friday, September 26th. Danaher's payout ratio is currently 27.23%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.